BS_BVSW4GTG
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 37.8
- os_event
- true
- age_years
- 0.318
- sex
- F
- race
- White
- new_clusters
- S2
- umap1_2d
- -0.472806765
- umap2_2d
- -8.472365756
- umap1_3d
- -3.943444871
- umap2_3d
- -2.079627856
- umap3_3d
- 5.795794961
- dataset
- Med-CBTN
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.490
- G2M_CHECKPOINT+0.480
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.450
- NOTCH_SIGNALING+0.420
- UV_RESPONSE_DN+0.400
- INTERFERON_ALPHA_RESPONSE+0.360
- MITOTIC_SPINDLE+0.360
- ANDROGEN_RESPONSE+0.350
- CHOLESTEROL_HOMEOSTASIS+0.330
- IL6_JAK_STAT3_SIGNALING+0.320
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.190
- DNA_REPAIR-0.160
- HEME_METABOLISM-0.120
- KRAS_SIGNALING_DN-0.120
- APICAL_SURFACE-0.050
- MYOGENESIS-0.050
- ADIPOGENESIS-0.040
- FATTY_ACID_METABOLISM-0.030
- PEROXISOME-0.020
- XENOBIOTIC_METABOLISM-0.020
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-2865 | Med | Medulloblastoma | 0.872 |
| 2 | TCGA-CQ-5326-01A-01R-1873-07 | — | — | 0.858 |
| 3 | MDT-AP-3069 | Med | Medulloblastoma | 0.850 |
| 4 | MDT-AP-0731 | Med | Medulloblastoma | 0.848 |
| 5 | MDT-AP-3337 | Med | Medulloblastoma | 0.844 |
| 6 | TCGA-FD-A3SO-01A-11R-A22U-07 | — | — | 0.837 |
| 7 | MDT-AP-3336 | Med | Medulloblastoma | 0.831 |
| 8 | TCGA-70-6722-01A-11R-1820-07 | — | cohortSQ1 | 0.828 |
| 9 | MDT-AP-3095 | Med | Medulloblastoma | 0.828 |
| 10 | MDT-AP-1236 | Med | Medulloblastoma | 0.825 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 38 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.490 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.480 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.450 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.420 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.400 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.360 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.360 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.350 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.330 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.320 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.280 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.260 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.260 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.250 | Inavolisib | — uncovered |
| COMPLEMENT | 0.240 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.240 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.230 | Idelalisib | — uncovered |
| APOPTOSIS | 0.210 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.190 | Inavolisib | — uncovered |
| HYPOXIA | 0.180 | Idelalisib | — uncovered |